跳至主要内容
临床试验/NCT01108679
NCT01108679已完成不适用

Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users

Albert Einstein College of Medicine2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2009年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Global Neurocognitive Function

研究概览

简要总结

The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive. In addition, blood samples will be stored for HIV+ and HIV- individuals who take buprenorphine to study its effect. This study hypothesizes that the HIV positive participants will demonstrate significant improvement in thinking and reasoning ability at 3 and 6 months compared to baseline, but that their thinking and reasoning ability will still be lower than HIV negative participants. This study also hypothesizes the biomarkers in participants' blood samples will be associated with measures of change in thinking and reasoning ability.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Documented HIV-serostatus
  • English-speaking
  • Age 18-60
  • Able to give voluntary, signed informed consent
  • Plan to initiate buprenorphine treatment in the next month.

排除标准

  • Over age 60: Participants over the age of 60 will be excluded, as normal age-associated cognitive changes may confound neuropsychological (NP) assessment and diagnosis of HIV-related cognitive disorders.
  • Neurologic: History of head injury with loss of consciousness for greater than 12 hours; previous penetrating skull wounds; previous brain surgery; known seizure disorder, or any other non-HIV related CNS disorders that might affect neurocognitive functioning (e.g., previous cerebrovascular accident, Parkinson's disease, multiple sclerosis, brain tumor).
  • Medical: e.g. collagen vascular disorder (e.g. lupus), oxygen requiring chronic pulmonary disease,, or end stage renal disease requiring dialysis.
  • Psychiatric: Lifetime diagnosis of schizophrenia or bipolar disorder.
  • Less than 6 years of education.
  • Acute intoxication due to alcohol or other drugs, as assessed by research staff.
  • Use of buprenorphine in the past month, either prescribed or purchased on the street.

结局指标

主要结局

Global Neurocognitive Function

时间窗: Months 3 and 6

Neurocognitive functioning in the domains of executive functioning, including decision making, processing speed, verbal memory, attention, and motor functioning

时间窗: Months 3 and 6

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Julia H. Arnsten

Prof., Dept of Medicine

Albert Einstein College of Medicine

研究点 (2)

Loading locations...

相似试验

Neurocognitive Effects of Buprenorphine Among HIV+... | 临床试验